Skip to main content
BSX
NYSE Industrial Applications And Services

Boston Scientific Q2 2026: 7% Organic Growth, $800M Restructuring, Penumbra Deal Advances

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$47.12
Mkt Cap
$69.457B
52W Low
$42.2
52W High
$109.5
52W Position info
12% above low
Off High info
57% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

BSX is trading near its 52-week low of $42.2 (12% above the low).

Summary

Boston Scientific posted Q2 2026 results with 7.0% organic growth and a new $700M–$800M restructuring plan. The Penumbra acquisition is progressing, and a $2B buyback was completed.


Key Events · Earnings and Guidance · BSX

  • Q2 2026 Results Beat

    Net sales of $5.442B (7.0% organic growth) and adjusted EPS of $0.86, driven by Interventional Cardiology and Electrophysiology. Gross margin expanded to 70.7%.

  • Major Restructuring Announced

    Board approved a $700M–$800M global restructuring plan on July 21, 2026, targeting $500M in annual pre-tax savings. Charges will be incurred through 2029, with most savings reinvested in growth.

  • Penumbra Acquisition Update

    The $14.5B acquisition of Penumbra received FTC Second Request; stockholder vote passed. Closing expected in H2 2026, funded by $11B in new debt and stock.

  • $2B Share Buyback Completed

    An accelerated share repurchase agreement settled in June, retiring approximately 40 million shares. $3B remains under the $5B authorization.


Analysis · BSX · Industrial Applications And Services

A solid quarter delivered 7.0% organic sales growth and gross margin expansion to 70.7%, but the spotlight shifts to the sweeping restructuring plan approved just after quarter-end. The $700M–$800M program aims to cut $500M in annual costs, signaling a major operational overhaul. Meanwhile, the $14.5B Penumbra acquisition remains on track for H2 2026 despite an FTC Second Request, and the company deployed $2B in share buybacks. Litigation noise persists with a securities class action and $76M in charges, though a key patent case was won on appeal. The quarter itself was strong, but the restructuring and M&A updates will dominate the narrative.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BSX was trading at $47.12 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $69.5B. The 52-week trading range was $42.20 to $109.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BSX - Latest Insights

BSX
Nov 02, 2026, 5:54 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $44.16
Real-time Price: $44.23 info
Change: +$0.070 (+0.16%) info
Market Cap: $64.067B info
BSX
Nov 02, 2026, 5:26 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $44.24
Real-time Price: $44.23 info
Change: -$0.010 (-0.02%) info
Market Cap: $64.067B info
BSX
Oct 29, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $42.15
Real-time Price: $44.23 info
Change: +$2.08 (+5%) info
Market Cap: $64.067B info
BSX
Oct 28, 2026, 10:52 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $42.11
Real-time Price: $44.23 info
Change: +$2.13 (+5%) info
Market Cap: $64.067B info
BSX
Oct 28, 2026, 6:34 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $42.85
Real-time Price: $44.23 info
Change: +$1.38 (+3%) info
Market Cap: $64.067B info